Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg with Active Juvenile Idiopathic Arthritis (JIA)

Registry ID

EUCTR2009-013091-40

Source registry

EUCTR

Phase

PHASE3

Sponsor

Abbott GmbH & Co. KG

Last update

2026-08-16

Conditions

• Juvenile Idiopathic Arthritis (JIA)

Summary

The primary objective of this study is to evaluate the safety of adalimumab in subjects 2 to < 4 years of age and subjects age 4 and above that weigh < 15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA.

Locations

• , , France
• , , Germany
• , , Sweden
• , , Slovakia
• , , Czechia
• , , Denmark

Related clinical trials

• OLE Study With Filgotinib in JIA
• Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
• The BRIDGE Pain Study
• Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis
• Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients
• Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

View on source registry